



Sosei Announces its Intention to Remain Listed on the Mothers Market

Tokyo, Japan – 17 March 2017: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) announced today that it intends to remain listed on the Mothers Market.

Sosei had advised in 2015 that it would apply to change its listing market from Mothers to Section 1 of the Tokyo Stock Exchange during the fiscal year ended March 2017.

The Tokyo Stock Exchange Listing Requirements for Section 1 includes a profitability requirement related to the two years prior to application. As already disclosed, Sosei made an Operating Loss in the fiscal year ended March 2016 and is therefore ineligible to apply for listing in Section 1 of the Tokyo Stock Exchange and will remain, for the time being, on the Mothers market.

Peter Bains, Chief Executive Officer of Sosei, said; “The Company’s Board is fully committed to creating long-term sustainable shareholder value through investment in R&D and in building a strong proprietary pipeline of innovative drug candidates from our unique Heptares platform. We are happy to remain for the time being on the Mothers market which is aligned to the current phase of Sosei’s evolution.”

-Ends-

Contact for Sosei
Harumi BANSE, Investor Relations
+81-(0)3-5210-3399
hbanse@sosei.com

Notes to Editors

About Sosei

Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei have established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei have already delivered two bronchodilators for COPD which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, MedImmune, MorphoSys, Teva, and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.

For further information about Sosei, please visit www.sosei.com/en.

###

**Forward-looking statements**

This press release contains "forward-looking statements" that are based upon the current beliefs and expectations of Sosei's management and are subject to significant risks and uncertainties. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.